Propagation of inflammatory signals from the airspace to the vascular space is pivotal in lung inflammation, but mechanisms of intercompartmental signaling are not understood. To define signaling mechanisms, we microinfused single alveoli of blood-perfused rat lung with TNF-α, and determined in situ cytosolic Ca 2+ concentration ([Ca 2+ ] i ) by the fura-2 ratio method, cytosolic phospholipase A 2 (cPLA 2 ) activation and P-selectin expression by indirect immunofluorescence. Alveolar TNF-α increased [Ca 2+ ] i and activated cPLA 2 in alveolar epithelial cells, and increased both endothelial [Ca 2+ ] i and P-selectin expression in adjoining perialveolar capillaries. All responses were blocked by pretreating alveoli with a mAb against TNF receptor 1 (TNFR1). Crosslinking alveolar TNFR1 also increased endothelial [Ca 2+ ] i . However, the endothelial responses to alveolar TNF-α were blocked by alveolar preinjection of the intracellular Ca 2+ chelator BAPTA-AM, or the cPLA 2 blockers AACOCF 3 and MAFP. The gap-junction uncoupler heptanol had no effect. We conclude that TNF-α induces signaling between the alveolar and vascular compartments of the lung. The signaling is attributable to ligation of alveolar TNFR1 followed by receptor-mediated [Ca 2+ ] i increases and cPLA 2 activation in alveolar epithelium. These novel mechanisms may be relevant in the alveolar recruitment of leukocytes.
ImmunoResearch Laboratories Inc. (West Grove, Pennsylvania, USA). FITC-conjugated donkey anti-goat IgG came from ICN Biomedicals Inc. (Costa Mesa, California, USA). Goat anti-mouse IgG (Fc-specific; Sigma Chemical Co., St. Louis, Missouri, USA) and goat antirabbit IgG (Jackson ImmunoResearch Laboratories Inc.) were also purchased. Mouse anti-rat P-selectin mAbs RMP-1 and RP-2 were gifts of A.C. Issekutz (Department of Pediatrics, Microbiology-Immunology and Pathology, Dalhousie University, Halifax, Nova Scotia, Canada) (23) .
Other agents used were fura-2 AM and HOECHST 33342 (Molecular Probes Inc., Eugene, Oregon, USA), TNF-α, arachidonic acid, linoleic acid, heptanol, indomethacin (all from Sigma Chemical Co.), saponin (ICN Biomedicals Inc.), the PLA 2 inhibitors AACOCF 3 , MAFP, and BEL, the Ca 2+ i chelator 1,2-bis-(o-aminophenophenoxyethane)-N,N,N′,N′-tetraacetic acid tetra-(acetoxymethyl)-ester (BAPTA-AM; Calbiochem-Novabiochem Corp., San Diego, California, USA), MK886 (Biomol Research Laboratories, Plymouth Meeting, Pennsylvania, USA), and WEB 2170BS (gift of Boehringer Ingelheim Inc., Ridgefield, Connecticut, USA). Intracapillary infusions were given in vehicle consisting of 2% dextran (70 kDa; Pharmacia Biotech Inc., Piscataway, New Jersey, USA), 1% FBS (Gemini Bio-Products Inc., Calabasas, California, USA), HEPES solution at pH 7.4 and osmolarity of 295 ± 5 mOsm, containing (in mmol/L) 150 Na + , 5 K + , 1 Ca 2+ , and 10 glucose. Intra-alveolar infusions were given in vehicle consisting of 0.1% delipidated BSA (fraction V; Sigma Chemical Co.) and Ringer's solution at pH 7.4 and osmolarity of 295 ± 5 mOsm, containing (in mmol/L) 137 Na + , 2.7 K + , 1 Ca 2+ , and 28 lactate.
Lung fluorescence microscopy. The microscopy methods have been described (20, 21) . Briefly, lungs excised from anesthetized Sprague-Dawley rats were continuously pump-perfused at 14 mL/min with autologous rat blood at 37°C. Lungs were constantly inflated at an airway pressure of 5 cmH 2 O. Pulmonary artery and left atrial pressures were held at 10 cmH 2 O and 5 cmH 2 O, respectively. The lung surface was kept moist with normal saline at 37°C and viewed by epifluorescence microscopy.
Fluorophores were excited by mercury lamp illumination directed through appropriate filters. Fluorescence emission was collected through objective lenses (Wplan FL ×40 UV; Olympus America Inc., Melville, New York, USA, or Ph3 Neofluar ×100; Carl Zeiss Jena GmbH, Jena, Germany) and dichroic and emission filters (400DCLPO2 and 510WB40; Omega Optical Inc., Brattleboro, Vermont, USA, or DM500 and O-515; Olympus America Inc.) by image intensifier (KS1381; Video Scope International Ltd., Sterling, Virginia, USA) and video camera (CCD-72; Dage-MTI Inc., Michigan City, Indiana, USA), then subjected to digital image analysis (MCID-M4; Imaging Research Inc., St. Catharine's, Ontario, Canada).
Substance delivery. For intra-alveolar infusions, a single alveolus was selected. The microscope objective was adjusted until the maximum diameter of the alveolus came into focus. By micropuncture, the alveolus was infused to fill 3-4 neighboring (nonmicropunctured) alveoli. One of the nonmicropunctured alveoli was selected for imaging. Intracapillary infusions were given either by capillary micropuncture or by a wedged venous microcatheter (PE-10; Baxter Diagnostics Inc., Deerfield, Illinois, USA) as described (20, 21) . Agents were infused in the following concentrations: fura-2 AM, 10 µM; HOECHST 33342, 5 µg/mL; TNF-α, 10-10,000 U/mL; arachidonic acid, 0.1-10 µM; linoleic acid, 10 µM; BAPTA-AM, 40 µM; heptanol, 3 mM; AACOCF 3 , 1 µM; MAFP, 25 µM; BEL, 1 µM; indomethacin, 20 µM; MK886, 1 µM; WEB 2170BS, 50 µM; saponin, 0.01%. These substances were all given by alveolar infusion. TNF-α, fura-2, and heptanol were also given by capillary infusion. BAPTA-AM was given in Ca 2+ -free Ringer's solution. Capillary blood cell-free or Ca 2+ -free conditions were established by infusion of 2% dextran HEPES solution that was either Ca 2+ -rich or Ca 2+ -free (containing 0.5 mmol/L EGTA), 10 minutes before measurements were taken.
[Ca 2+ ] i imaging. Our in situ methods have been reported (20) . For epithelial and endothelial [Ca 2+ ] i determinations, fura-2 AM (which deesterifies intracellularly to impermeant fura-2), was given for 30 minutes by intra-alveolar or intracapillary infusion, respectively. Infused alveoli were washed with 3% reconstituted bovine surfactant (Survanta; Abbott Laboratories, Columbus, Ohio, USA). Alveoli and capillaries loaded with fura-2 were excited at 340 nm and 380 nm, and [Ca 2+ ] i was determined from the computer-generated 340:380 ratio based on a K d of 224 nmol/L and appropriate calibration parameters (20, 24) . Dominant oscillation frequency and amplitude were determined for [Ca 2+ ] i oscillations of amplitude greater than 15 nM using fast Fourier transformation (Origin V 4.0; Microcal Software Inc., Northampton, Massachusetts, USA).
Indirect immunofluorescence in situ. These methods have been described (21) . To determine epithelial TNFR1 expression, an alveolus was infused first with E-20 (10 µg/mL) or control mAb RP-2 (10 µg/mL) for 10 minutes, then with the secondary FITC-conjugated mAb (75 µg/mL) for 1 minute. Unbound fluorescence was removed by infusion of Ringer's solution. To determine endothelial P-selectin expression, RMP-1 (35 µg/mL) was infused into a single capillary for 10 minutes, then secondary FITC-conjugated mAb (1:20) was infused for 1 minute. Unbound fluorescence was removed by blood flow in less than 30 seconds (21) . Residual FITC fluorescence indicated expression of the targeted antigen. To assess activation of cPLA 2 , we adapted an immunofluorescence assay reported in vitro (25) that involves permeabilization of the cell membrane by 0.5% Triton X-100. Membrane permeabilization not only permits cell loading with primary and secondary Abs, but also causes loss of unbound cytoplasmic molecules such as nonactivated cPLA 2 when cells are subsequently washed. Hence, no immunofluorescent staining for cytoplasmic cPLA 2 is detectable in unstimulated cells. However, in activated cells, staining occurs on the translocated fraction of cPLA 2 that becomes membrane bound and thus remains intracellular. Therefore, to carry out the assay, we first infused an alveolus for 5 minutes with TNF-α or vehicle, then fixed and permeabilized the alveolus by infusion of 4% paraformaldehyde and 0.5% Triton X-100 for 10 minutes and 4 minutes, respectively. We then infused the alveolus with anti-rat cPLA 2 Ab (1:5) and FITC-conjugated IgG (1:10), followed by alveolar washes with infusions of Ringer's solution. Residual fluorescence indicated the presence of activated, membrane-bound cPLA 2 (25) . Alveolar epithelial nuclei were stained in situ by alveolar infusion of HOECHST 33342 (26) followed by a wash.
Receptor crosslinking in situ. Crosslinking of the alveolar TNFR1 was performed by sequential intra-alveolar infusions of E-20 (10 µg/mL), secondary anti-goat IgG (60 µg/mL), and finally Ringer's solution to wash the alveolus. For control, the isotype-matched mAb RP-2 (10 µg/mL) replaced E-20 in the crosslinking protocol.
Statistics. All data are mean ± SEM. Values of several groups were compared using the Wilcoxon and Friedman test for dependent groups, and Kruskal-Wallis and Mann-Whitney U tests for independent groups. Linear regression analysis was performed using SigmaPlot (Jandel Scientific Software, San Rafael, California, USA). Statistical significance was accepted at P < 0.05.
Results
Using indirect immunofluorescence in situ, we confirmed the uniform presence of TNFR1 in alveoli (Figure 1a) . No alveolar fluorescence was detected with the isotype-matched control mAb RP-2, which recognizes rat tissue but not alveolar epithelial antigen. Epithelial [Ca 2+ ] i was determined in several cells of the imaged alveolus. Endothelial responses were similar in lung venular and alveolar septal capillaries, therefore we have not distinguished between these locations in reporting the data.
Because our procedures involved alveolar micropuncture, we confirmed that no capillary fluorescence was detectable 30 minutes after an intra-alveolar infusion of FITC-conjugated IgG, which ruled out macromolecular leakage across the alveolar membrane (n = 3; not shown).
Intra-alveolar TNF-α. We gave intra-alveolar TNF-α infusion for 10 seconds. As exemplified by the alveolocapillary unit shown in Figure 1b In experiments that are not shown here, we confirmed that the nonspecific mAb RP-2 caused no [Ca 2+ ] i responses, either as the primary mAb in the crosslinking protocol (n = 3) or as a control for the inhibitory effect of E-20 (n = 3). Hence, the crosslinking and blocking effects of E-20 were specific to receptor ligation. We also confirmed that when E-20 and TNF-α were both given sequentially by capillary infusion, endothelial [Ca 2+ ] i increases were blocked (P < 0.05). However, capillary infusion of E-20 did not block [Ca 2+ ] i increases to alveolar infusion of TNF-α (n = 4; not shown).
Ca 2+ i chelation. A 15-minute alveolar infusion of the membrane-permeable intracellular Ca 2+ i chelator BAPTA-AM blocked both epithelial and endothelial
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The Activation of cPLA 2 . TNF-α causes Ca 2+ -dependent activation of cPLA 2 , leading to arachidonate release (28) . Activated cPLA 2 translocates to cellular membranes and the nuclear envelope (25) . Immunofluorescence of membrane-bound cPLA 2 was detectable in several epithelial cells in single alveoli infused with TNF-α (Figure 6a ). Overlaying images for cPLA 2 immunofluorescence ( Figure 6b ) and nuclear fluorescence ( Figure  6c ) revealed close apposition of cPLA 2 to the nucleus (Figure 6d ), indicating that cPLA 2 was translocated to the perinuclear region. No cPLA 2 staining was detected when alveoli were infused with Ringer's solution before immunofluorescence labeling (Figure 6e ), although nuclear staining was positive (Figure 6f) . Alveolar infusions of the cPLA 2 inhibitor AACOCF 3 , given 10 minutes before alveolar TNF-α infusion, blocked the endothelial [Ca 2+ ] i response (P < 0.05) but not the epithelial response (Figure 7a, left) . Endothelial [Ca 2+ ] i increases were rescued in the presence of intraalveolar AACOCF 3 by capillary infusion of TNF-α (P < 0.05; Figure 7a , right). We interpret this to mean that AACOCF 3 given by the alveolar route did not block direct endothelial responses to TNF-α.
AACOCF 3 given by alveolar infusion 5 minutes after alveolar infusion of TNF-α terminated the endothelial [Ca 2+ ] i response in less than 2 minutes (P < 0.05; Figure  7b ), indicating that even after the onset of the endothelial response it was quickly abrogated by the cPLA 2 inhibitor. Similarly to AACOCF 3 , alveolar infusion of MAFP, an inhibitor of both Ca 2+ -dependent PLA 2 (cPLA 2 ) and Ca 2+ -independent PLA 2 (iPLA 2 ), blocked endothelial responses to alveolar TNF-α (P < 0.05). However, BEL, which inhibits iPLA 2 , had no inhibitory effect on the endothelial [Ca 2+ ] i response (n = 4 each; not shown).
Endothelial responses to alveolar infusion of TNF-α were not blocked by preinfusing alveoli with indomethacin (a cyclooxygenase blocker), MK886 (a 5-lipoxygenase-activating protein inhibitor), or WEB 2170BS (the platelet-activating factor receptor antagonist) (Figure 7c ), suggesting that these mechanisms were not essential to the observed responses. However, in permeabilized alveoli, arachidonate infusion induced concentration-dependent increases of endothelial [Ca 2+ ] i (P < 0.05; Figure 7d ). Hence, arachidonate induced endothelial responses from the alveolar aspect of the capillary. No arachidonate effects occurred in nonpermeabilized alveoli. These findings were replicated by intra-alveolar linoleate (10 µM), which also caused endothelial [Ca 2+ ] i increases in capillaries adjacent to permeabilized, but not nonpermeabilized, alveoli (P < 0.05, n = 4; not shown). P-selectin. Endothelial [Ca 2+ ] i increase may induce expression of the leukocyte-endothelial adhesion molecule P-selectin (18, 21) . We quantified P-selectin expression in intact venular capillaries using our previously described methods (21) . As shown in Figure 8 , within 5 minutes of alveolar infusion of TNF-α, Pselectin expression increased approximately 10-fold above baseline. This increase was blocked by anti-TNFR1 mAb, BAPTA-AM, and AACOCF 3 . Neither infusion with Ringer's solution nor the isotypematched control mAb RP-2 had any observable effects.
Discussion
We show here the existence of novel epithelialendothelial signaling mechanisms in the lung. Our main conclusions are as follows. First, from finding (a), we conclude that an alveolar stimulus induced Ca 2+ signaling in endothelial cells of perialveolar capillaries. Second, from findings [(b) and (c)] we conclude that the TNF-α effect followed ligation of alveolar TNFR1. Third, from findings (d) and (e) we conclude that the endothelial [Ca 2+ ] i response was attributable to the epithelial [Ca 2+ ] i increase and to activation of epithelial cPLA 2 . Fourth, from finding (f) we conclude that the endothelial response was proinflammatory. In addition, the gap-junction uncoupler heptanol failed to inhibit endothelial responses to alveolar TNF-α, thereby ruling out a gap-junctional basis for alveolocapillary signaling. Taken together, these findings are the first evidence that adjacent epithelial and endothelial cells of the alveolocapillary junction communicate Ca 2+ signals through a receptor-mediated mechanism initiated in the epithelium.
Methodological considerations
Compartmental localization. Alveolar leak of TNF-α given by intra-alveolar infusion could be ruled out because: (a) Intra-alveolar TNF-α-induced endothelial effects were blocked by intra-alveolar infusion of E-20, BAPTA-AM, or cPLA 2 blockers. However, TNF-α given directly in capillaries still caused endothelial [Ca 2+ ] i increases. These results indicate that TNF-α did not
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The Interactions between TNF-α and cPLA 2 . Our in situ assay for cPLA 2 activation indicates a novel pulmonary role for cPLA 2 , namely its involvement in alveolocapillary signal propagation. Alveolar epithelial cells constitutively express cPLA 2 (32) . Both TNF-α and sustained [Ca 2+ ] i increases activate cPLA 2 (28, 33, 34) . By immunofluorescence assay, we determined that intraalveolar TNF-α induced membrane translocation and probably activation of cPLA 2 in alveolar epithelium (25) . Translocation was predominantly localized to the perinuclear region, the preferential site of agonist-stimulated phospholipid hydrolysis by cPLA 2 (35) .
Activation of cPLA 2 was supported by the inhibitory effects of the cPLA 2 blockers AACOCF 3 and MAFP, which block both the Ca 2+ -dependent and the Ca 2+ -independent cytosolic isoforms (cPLA 2 and iPLA 2 , respectively) (36, 37) . Although nonspecific effects may occur, we point out that these agents blocked the (36) , had no inhibitory effect. Taken together, these results suggest that the observed endothelial responses resulted from activation of Ca 2+ -dependent cPLA 2 in alveolar epithelium.
Products of cPLA 2 activation. Activation of cPLA 2 yields arachidonate, prostaglandins, leukotrienes, and platelet-activating factor (38, 39) . All of these products could potentially act as paracrine mediators. However, inhibitors of prostaglandin or leukotriene synthesis, or of the platelet-activating factor receptor, had no inhibitory effects on alveolocapillary signal propagation. Hence, to the extent that we can determine, these products did not convey the propagated signal. Although unidentified products may have contributed to the endothelial effect of alveolar TNF-α, cPLA 2 specifically releases arachidonate from the sn-2 position of phospholipids (35) . Therefore, the alveolocapillary signal may have been conveyed by arachidonate.
To the extent that arachidonate is secreted (37) and directly causes Ca 2+ entry into cells (40, 41) , it may have exerted a paracrine effect. We cannot directly confirm arachidonate secretion into the alveolocapillary space, but there is indirect support of this possibility. effect of basolaterally secreted arachidonate from alveolar epithelial cells. We considered that arachidonate may also be secreted into the alveolar lumen by alveolar epithelial cells, and that the luminal fatty acid may cross the alveoli and act on adjacent capillaries. Although to our knowledge transalveolar fatty acid transport has not been confirmed, fatty acids are capable of crossing cell membranes (42) , and when present in the alveolar lumen, they may cross the alveolar barrier by entering cells apically and exiting basolaterally. We tested this possibility for 2 polyunsaturated fatty acids, arachidonate and linoleate, given by intra-alveolar infusion. Both are known to increase [Ca 2+ ] i in cultured cells (43) . However, in intact alveoli, neither was apparently transported across the alveolar barrier at a sufficient level to evoke [Ca 2+ ] i transients in the adjoining capillary. By contrast, in permeabilized alveoli, arachidonate and linoleate both induced endothelial [Ca 2+ ] i increases. These findings indicate that an alveolar barrier to FFA transport existed, and that its elimination was necessary to allow sufficient action of alveolar FFAs on adjacent capillaries. The barrier may be attributable to transport limitations across cell membranes as well as to fatty acid metabolism within the cell. We interpret that to the extent that arachidonate released by alveolar epithelial cells caused the observed endothelial responses, its substantive effect resulted from basolateral rather than apical secretion.
P-selectin. The goal of alveolocapillary signaling is to induce enhanced expression of leukocyte adhesion receptors in endothelial cells, in order to activate leukocyte influx. We tested this hypothesis in the context of Pselectin expression. Alveolar TNF-α enhanced endothelial P-selectin expression within 5 minutes. This response resembles the [Ca 2+ ] i -dependent P-selectin expression we recently reported in pressure-stressed lung capillaries (21) . Although platelets also express P-selectin, we previously reported that these capillaries are free of adherent platelets, and that P-selectin expression occurs in the presence of cell-free capillary infusion (21) . Because endothelial P-selectin expression is a hallmark of early inflammation (44) and may precede neutrophil adhesion and emigration (19) , we interpret that receptormediated alveolocapillary signaling evoked a rapid proinflammatory effect in perialveolar capillaries.
Inhibition of the P-selectin response permitted interpretation of the sequence of signaling events. Because alveolar E20 blocked all responses, we consider TNFR1 ligation to be the first step in the sequence. All intraalveolar interventions such as BAPTA-AM and AACOCF 3 that blocked epithelial responses also blocked endothelial [Ca 2+ ] i increases and P-selectin expression. Hence, the epithelial responses were causal to endothelial signals that led to P-selectin expression. Although we did not directly determine kinetics along the signaling pathway, we determined that the epithelial [Ca 2+ ] i increases and the resulting endothelial [Ca 2+ ] i increases were detectable in 2 minutes, whereas epithelial cPLA 2 activation and endothelial P-selectin expression were detectable in 5 minutes. These results agree with reported time courses of P-selectin upregulation and cPLA 2 translocation (45, 46) . Based on these considerations, we conclude that alveolar TNF-α caused rapid capillary expression of a leukocyte adhesion receptor. This resulted from sequential events in which alveolar TNFR1 ligation caused [Ca 2+ ] i increase and cPLA 2 activation in alveolar epithelium, which was followed by an increase of endothelial [Ca 2+ ] i in adjacent capillaries.
Conclusions
Our findings provide the first direct evidence that alveoli communicate inflammatory signals to perialveolar capillaries. This intercompartmental signaling may be essential for effective host defense against airspace pathogens. Previous reports indicate that alveolar neutrophil influx after lung instillation of TNF-α occurs over a period of hours (7). Here we show that intra-alveolar TNF-α causes an endothelial proinflammatory response in minutes. This indicates that an alveolar stimulus is capable of immediately inducing alveolocapillary signaling, although the full scope of the response may develop over a much longer period. To summarize, TNF-α initiates ligation and clustering of the alveolar epithelial TNFR1, mobilization of epithelial [Ca 2+ ] i , and the translocation and perhaps activation of epithelial cPLA 2 . This may, through basolateral arachidonate secretion from alveolar epithelial cells, account for endothelial [Ca 2+ ] i influx and therefore enhanced expression of P-selectin. The extent to which these findings apply to other inflammatory ligands in the alveolus requires further investigation.
